Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review

References

• Karch CP, Burkhard P. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120:1–4.
   PubMed Web of Science ®Google Scholar
• Brenner S, Jacob F, Meselson M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature. 1961;190:576–581.
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Understanding mRNA COVID-19 vaccines; 2021.
   Google Scholar
• Thran M, Mukherjee J, Pönisch M, et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017;9(10):1434–1447.
   PubMed Web of Science ®Google Scholar
• Cao L, Zheng ZC, Zhao YC, et al. Gene therapy of Parkinson’s disease model rat by direct injection of plasmid DNA–lipofectin complex. Hum Gene Ther. 1995;6(11):1497–1501.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, Phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
   PubMed Web of Science ®Google Scholar
• Martinon F, Krishnan S, Lenzen G, et al. Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA. Eur J Immunol. 1993;23(7):1719–1722.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Lipsitch M, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–2100.
   PubMed Web of Science ®Google Scholar
• Tang P. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27:2136–2143.
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery, and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–838.
   PubMed Web of Science ®Google Scholar
• Krieg PA, Melton DA. in vitro transcription of cloned cDNAs. Nucleic Acids Res. 1984;12:7057–7070.
   PubMed Web of Science ®Google Scholar
• Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021;41(3):509–518.
   PubMed Web of Science ®Google Scholar
• Damiati LA, El-Messeiry S. An Overview of RNA-Based Scaffolds for Osteogenesis. Front Mol Biosci. 2021;8:682581. doi:10.3389/fmolb.2021.682581
   PubMed Web of Science ®Google Scholar
• Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Mol Ther. 2019;27(4):710–728. doi:10.1016/j.ymthe.2019.02.012
   PubMed Web of Science ®Google Scholar
• Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.
   PubMed Web of Science ®Google Scholar
• Ho W, Gao M, Li F, Li Z, Zhang XQ, Xu X. Next‐generation vaccines: nanoparticle‐mediated DNA and mRNA delivery. Adv Healthcare Mater. 2021;10(8):2001812.
   Web of Science ®Google Scholar
• Granot Y, Peer D. Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics—An innate immune system standpoint. Seminars Immunol. 2017;34:68–77.
   PubMed Web of Science ®Google Scholar
• Guevara ML, Persano S, Persano F. Lipid-based vectors for therapeutic mRNA-based anti-cancer vaccines. Curr Pharm Des. 2019;25(13):1443–1454.
   PubMed Web of Science ®Google Scholar
• Fang E, Liu X, Li M, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduction Targeted Therapy. 2022;7(1):94.
   PubMed Web of Science ®Google Scholar
• Iavarone C, O’hagan DT, Yu D, Delahaye NF, Ulmer JB. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017;16(9):871–881.
   PubMed Web of Science ®Google Scholar
• Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780.
   PubMed Web of Science ®Google Scholar
• Tourriere H, Chebli K, Tazi J. mRNA degradation machines in eukaryotic cells. Biochimie. 2002;84(8):821–837.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Mc Cafferty S, Combes F, et al. mRNA therapeutics deliver a hopeful message. Nano Today. 2018;23:16–39.
   Web of Science ®Google Scholar
• Weissman D. mRNA transcript therapy. Expert Rev Vaccines. 2015;14(2):265–281.
   PubMed Web of Science ®Google Scholar
• Nance KD, Meier JL. Modifications in an emergency: the role of N1-methyl pseudouridine in COVID-19 vaccines. ACS Central Sci. 2021;7(5):748–756.
   PubMed Web of Science ®Google Scholar
• Chamberlin M, Mcgrath J, Waskell L. New RNA polymerase from Escherichia coli infected with bacteriophage T7. Nature. 1970;228:227–231.
   PubMed Web of Science ®Google Scholar
• Chamberlin M, Kingston R, Gilman M, Wiggs J, De Vera A. Isolation of bacterial and bacteriophage RNA polymerases and their use in the synthesis of RNA in Vitro. Methods Enzymol. 1983;101:540–568.
   PubMed Web of Science ®Google Scholar
• Krieg PA, Melton DA. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 1984;12(18):7057–7070. doi:10.1093/nar/12.18.7057
   PubMed Web of Science ®Google Scholar
• Li B, Luo X, Dong Y. Effects of chemically modified messenger RNA on protein expression. Bioconjug Chem. 2016;27(3):849–853.
   PubMed Web of Science ®Google Scholar
• Kimoto M, Meyer AJ, Hirao I, Ellington AD. Genetic alphabet expansion transcription generating functional RNA molecules containing a five-letter alphabet including modified unnatural and natural base nucleotides by thermostable T7 RNA polymerase variants. Chem Commun. 2017;53(91):12309–12312.
   PubMed Web of Science ®Google Scholar
• Milisavljevič N, Perlíková P, Pohl R, Hocek M. Enzymatic synthesis of base-modified RNA by T7 RNA polymerase. A systematic study and comparison of 5-substituted pyrimidine and 7-substituted 7-deazapurine nucleoside triphosphates as substrates. Org Biomol Chem. 2018;16(32):5800–5807.
   PubMed Web of Science ®Google Scholar
• Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl (3′-O-methyl) GpppG and 7-methyl (3′-deoxy) GpppG. RNA. 2001;7(10):1486–1495.
   PubMed Web of Science ®Google Scholar
• Fath S, Bauer AP, Liss M, et al. Multiparameter RNA, and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One. 2011;6(3):e17596.
   PubMed Web of Science ®Google Scholar
• Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–4017.
   PubMed Web of Science ®Google Scholar
• Trepotec Z, Geiger J, Plank C, Aneja MK, Rudolph C. Segmented poly (A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA. 2019;25(4):507–518.
   PubMed Web of Science ®Google Scholar
• To KK, Cho WC. An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin Drug Discov. 2021;16(11):1307–1317.
   PubMed Web of Science ®Google Scholar
• Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Therapy. 2008;16(11):1833–1840.
   PubMed Web of Science ®Google Scholar
• Mauger DM, Cabral BJ, Presnyak V, et al. mRNA structure regulates protein expression through changes in functional half-life. Proce National Acad Sci. 2019;116(48):24075–24083.
   PubMed Web of Science ®Google Scholar
• Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5′-untranslated regions of eukaryotic mRNAs. Science. 2016;352(6292):1413–1416.
   PubMed Web of Science ®Google Scholar
• Babendure JR, Babendure JL, Ding JH, Tsien RY. Control of mammalian translation by mRNA structure near caps. RNA. 2006;12(5):851–861.
   PubMed Web of Science ®Google Scholar
• Kozak M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene. 2005;361:13–37.
   PubMed Web of Science ®Google Scholar
• Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731–745.
   PubMed Web of Science ®Google Scholar
• Haizel SA, Bhardwaj U, Gonzalez RL, Mitra S, Goss DJ. 5′-UTR recruitment of the translation initiation factor eIF4GI or DAP5 drives cap-independent translation of a subset of human mRNAs. J Biol Chem. 2020;295(33):11693–11706.
   PubMed Web of Science ®Google Scholar
• Elroy-Stein O, Fuerst TR, Moss B. Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5’sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proce National Acad Sci. 1989;86(16):6126–6130.
   PubMed Web of Science ®Google Scholar
• Tan X, Wan Y. Enhanced protein expression by IRES-driven mRNA translation as a novel approach for in vitro loading dendritic cells with antigens. Human Immunol. 2008;69(1):32–40.
   PubMed Web of Science ®Google Scholar
• Balzer Le S, Onsager I, Lorentzen JA, Lale R. Dual UTR-A novel 5′ untranslated region design for synthetic biology applications. Synthetic Biol. 2020;5(1):ysaa006.
   Google Scholar
• Leppek K, Das R, Barna M. Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat Rev Mol Cell Biol. 2018;19(3):158–174.
   PubMed Web of Science ®Google Scholar
• Asrani KH, Farelli JD, Stahley MR, et al. Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 2018;15(6):756–762.
   PubMed Web of Science ®Google Scholar
• Mayr C. Regulation by 3′-untranslated regions. Annu Rev Genet. 2017;51:171–194.
   PubMed Web of Science ®Google Scholar
• Matoulkova E, Michalova E, Vojtesek B, Hrstka R. The role of the 3’untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol. 2012;9(5):563–576.
   PubMed Web of Science ®Google Scholar
• Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res. 2005;33(22):7138–7150.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu XS, Russell JE. A nucleolin-binding 3′ untranslated region element stabilizes β-globin mRNA in vivo. Mol Cell Biol. 2006;26(6):2419–2429.
   PubMed Web of Science ®Google Scholar
• Eberhardt W, Doller A, Akool ES, Pfeilschifter J. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther. 2007;114(1):56–73.
   PubMed Web of Science ®Google Scholar
• Wilkinson N, Pantopoulos K. The IRP/IRE system in vivo: insights from mouse models. Front Pharmacol. 2014;5:176.
   PubMed Web of Science ®Google Scholar
• Yu S, Kim VN. A tale of non-canonical tails: gene regulation by post-transcriptional RNA tailing. Nat Rev Mol Cell Biol. 2020;21(9):542–556.
   PubMed Web of Science ®Google Scholar
• Tang TT, Passmore LA. Recognition of poly (A) RNA through its intrinsic helical structure. Cold Spring Harbor Symposia Quantitative Biol. 2019;84:21–30.
   PubMedGoogle Scholar
• Goldstrohm AC, Wickens M. Multifunctional deadenylase complexes diversify mRNA control. Nat Rev Mol Cell Biol. 2008;9(4):337–344.
   PubMed Web of Science ®Google Scholar
• Natalizio BJ, Wente SR. Postage for the messenger: designating routes for nuclear mRNA export. Trends Cell Biol. 2013;23(8):365–373.
   PubMed Web of Science ®Google Scholar
• Bresson SM, Conrad NK. The human nuclear poly (a)-binding protein promotes RNA hyper adenylation and decay. PLoS Genet. 2013;9(10):e1003893.
   PubMed Web of Science ®Google Scholar
• Wu HY, Ke TY, Liao WY, Chang NY. Regulation of coronaviral poly (A) tail length during infection. PLoS One. 2013;8(7):e70548.
   PubMed Web of Science ®Google Scholar
• Gallie D. The cap and poly (A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 1991;5(11):2108–2116.
   PubMed Web of Science ®Google Scholar
• Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28(3–4):117–129.
   PubMed Web of Science ®Google Scholar
• McCullough KC, Milona P, Thomann-Harwood L, et al. Self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. Vaccines. 2014;2(4):735–754.
   PubMedGoogle Scholar
• Sandbrink JB, Shattock RJ. RNA vaccines: a suitable platform for tackling emerging pandemics?. Front Immunol. 2020;11:608460.
   PubMed Web of Science ®Google Scholar
• Beissert T, Perkovic M, Vogel A, et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Therapy. 2020;28(1):119–128.
   PubMed Web of Science ®Google Scholar
• Kairuz D, Samudh N, Ely A, Arbuthnot P, Bloom K. Advancing mRNA technologies for therapies and vaccines: An African context. Front Immunol. 2022;1:13.
   Google Scholar
• Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines. 2021;9(2):97.
   PubMed Web of Science ®Google Scholar
• Kim DY, Atasheva S, McAuley AJ, et al. Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs. Proc Natl Acad Sci U S A. 2014;111(29):10708–10713. doi:10.1073/pnas.1408677111
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Self-replicating RNA viruses for RNA therapeutics. Molecules. 2018;23(12):3310.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
   PubMed Web of Science ®Google Scholar
• Kwon H, Kim M, Seo Y, et al. The emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials. 2018;156:172–193.
   PubMed Web of Science ®Google Scholar
• Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35(3):222–229.
   PubMed Web of Science ®Google Scholar
• Lorenz C, Fotin-Mleczek M, Roth G, et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol. 2011;8(4):627–636.
   PubMed Web of Science ®Google Scholar
• Diken M, Kreiter S, Selmi A, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 2011;18(7):702–708.
   PubMed Web of Science ®Google Scholar
• Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319–334.
   PubMed Web of Science ®Google Scholar
• Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Materials. 2017;2(10):1–7.
   Web of Science ®Google Scholar
• Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12(2):102.
   PubMed Web of Science ®Google Scholar
• Schlich M, Palomba R, Costabile G, et al. Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioeng Translational Med. 2021;6(2):e10213.
   PubMed Web of Science ®Google Scholar
• Delehedde C, Even L, Midoux P, Pichon C, Perche F. Intracellular routing and recognition of lipid-based mRNA nanoparticles. Pharmaceutics. 2021;13(7):945.
   PubMed Web of Science ®Google Scholar
• Islam MA, Xu Y, Tao W, et al. Restoration of tumor-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nature Biomed Eng. 2018;2(11):850–864.
   PubMed Web of Science ®Google Scholar
• Iavarone C, Ramsauer K, Kubarenko AV, et al. A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. J Immunol. 2011;186(7):4213–4222.
   PubMed Web of Science ®Google Scholar
• Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21):e142.
   PubMed Web of Science ®Google Scholar
• Lokugamage MP, Gan Z, Zurla C, et al. Mild innate immune activation overrides efficient nanoparticle‐mediated RNA delivery. Adv Mater. 2020;32(1):1904905.
   Web of Science ®Google Scholar
• Pollard C, Rejman J, De Haes W, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Therapy. 2013;21(1):251–259.
   PubMed Web of Science ®Google Scholar
• Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Eng J Med. 2012;367(19):1814–1820.
   PubMed Web of Science ®Google Scholar
• world health organization (WHO). Middle East respiratory syndrome. MERS situation; 2021.
   Google Scholar
• Mu X, Hur S. Immunogenicity of in vitro-transcribed RNA. Acc Chem Res. 2021;54(21):4012–4023.
   PubMed Web of Science ®Google Scholar
• Hadas Y, Katz MG, Bridges CR, Zangi L. Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease. Wiley Interdiscip Rev Syst Biol Med. 2017;9(1):e1367.
   Web of Science ®Google Scholar
• Sartorius R, Trovato M, Manco R, D’Apice L, De Berardinis P. Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines. NPJ Vaccines. 2021;6(1):127.
   PubMed Web of Science ®Google Scholar
• Ganesan P, Narayanasamy D. Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustainable Chem Pharmacy. 2017;6:37–56.
   Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114–1125.
   PubMed Web of Science ®Google Scholar
• Freyn AW, da Silva JR, Rosado VC, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Therapy. 2020;28(7):1569–1584.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Qi Y, Wang M, et al. mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines. 2020;8(1):123.
   PubMed Web of Science ®Google Scholar
• Pardi N, LaBranche CC, Ferrari G, et al. Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques. Mol Therapy Nucleic Acids. 2019;15:36–47.
   PubMedGoogle Scholar
• Moyo N, Vogel AB, Buus S, et al. Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA. Mol Therapy Methods Clin Dev. 2019;12:32–46.
   PubMed Web of Science ®Google Scholar
• Mansanguan S, Charunwatthana P, Piyaphanee W, Dechkhajorn W, Poolcharoen A, Mansanguan C. Cardiovascular manifestation of the BNT162b2 mRNA COVID-19 vaccine in adolescents. Trop Med Infect Dis. 2022;7(8):196.
   PubMedGoogle Scholar
• Sinagra G, Merlo M, Porcari A. Exploring the possible link between myocarditis and mRNA COVID-19 vaccines. Eur J Intern Med. 2021;92:28–30.
   PubMed Web of Science ®Google Scholar
• Liang Y, Huang L, Liu T. Development and delivery systems of mRNA vaccines. Front Bioeng Biotechnol. 2021;9:718753.
   PubMed Web of Science ®Google Scholar
• Kuntz J, Crane B, Weinmann S, Naleway AL; Vaccine Safety Datalink Investigator Team. Myocarditis and pericarditis are rare following live viral vaccinations in adults. Vaccine. 2018;36(12):1524–1527.
   PubMed Web of Science ®Google Scholar
• Tarab-Ravski D, Stotsky-Oterin L, Peer D. Delivery strategies of RNA therapeutics to leukocytes. J Controlled Release. 2022;342:362–371.
   PubMed Web of Science ®Google Scholar
• Gutkin A, Rosenblum D, Peer D. RNA delivery with a human virus-like particle. Nat Biotechnol. 2021;39(12):1514–1515.
   PubMed Web of Science ®Google Scholar
• Igyártó BZ, Jacobsen S, Ndeupen S. Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr Opin Virol. 2021;48:65–72.
   PubMed Web of Science ®Google Scholar
• Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyártó BZ. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. Science. 2021;24(12):103479.
   Google Scholar
• Knop K, Hoogenboom R, Fischer D, Schubert US. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angewandte chemie int edition. 2010;49(36):6288–6308.
   PubMed Web of Science ®Google Scholar
• Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Controlled Release. 2013;172(1):38–47.
   PubMed Web of Science ®Google Scholar
• Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials. 2010;31(26):6867–6875.
   PubMed Web of Science ®Google Scholar
• Sedic M, Senn JJ, Lynn A, et al. Safety evaluation of lipid nanoparticle–formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Vet Pathol. 2018;55(2):341–354.
   PubMed Web of Science ®Google Scholar
• Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17:521–525.
   PubMed Web of Science ®Google Scholar
• Li S, Wu SP, Whitmore M, et al. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol Lung Cell Mol Physiol. 1999;276(5):L796–804.
   Web of Science ®Google Scholar
• Kowalzik F, Schreiner D, Jensen C, Teschner D, Gehring S, Zepp F. mRNA-Based Vaccines. Vaccines. 2021;9(4):390. doi:10.3390/vaccines9040390.
   PubMed Web of Science ®Google Scholar
• Wollner CJ, Richner JM. mRNA vaccines against flaviviruses. Vaccines. 2021;9(2):148.
   Web of Science ®Google Scholar
• Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20(1):33.
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30(12):1210–1216.
   PubMed Web of Science ®Google Scholar
• Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38(17):5884–5892.
   PubMed Web of Science ®Google Scholar
• Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–175.
   PubMed Web of Science ®Google Scholar
• Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell stem cell. 2010;7(5):618–630.
   PubMed Web of Science ®Google Scholar
• Nelson J, Sorensen EW, Mintri S, et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci Adv. 2020;6(26):eaaz6893.
   PubMed Web of Science ®Google Scholar
• Thess A, Grund S, Mui BL, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Therapy. 2015;23(9):1456–1464.
   PubMed Web of Science ®Google Scholar
• Al-Saif M, Khabar KS. UU/UA dinucleotide frequency reduction in coding regions results in increased mRNA stability and protein expression. Mol Therapy. 2012;20(5):954–959.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Azizian KT, Haque AA, et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Therapy Nucleic Acids. 2018;12:530–542.
   PubMedGoogle Scholar
• Krienke C, Kolb L, Diken E, et al. A noninflammatory mRNA vaccine for the treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145–153.
   PubMed Web of Science ®Google Scholar
• Starostina EV, Sharabrin SV, Antropov DN, et al. Construction and immunogenicity of modified mRNA-vaccine variants encoding influenza virus antigens. Vaccines. 2021;9(5):452.
   PubMed Web of Science ®Google Scholar
• Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021;601:120586.
   PubMed Web of Science ®Google Scholar
• Yang Q, Yu CH, Zhao F, et al. eRF1 mediates codon usage effects on mRNA translation efficiency through premature termination at rare codons. Nucleic Acids Res. 2019;47(17):9243–9258.
   PubMed Web of Science ®Google Scholar
• Triana-Alonso FJ, Dabrowski M, Wadzack J, Nierhaus KH. Self-coded 3′-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. J Biol Chem. 1995;270(11):6298–6307.
   PubMed Web of Science ®Google Scholar
• Gholamalipour Y, Karunanayake Mudiyanselage A, Martin CT. 3′ end additions by T7 RNA polymerase are RNA self-templated, distributive, and diverse—RNA-Seq analyses. Nucleic Acids Res. 2018;46(18):9253–9263.
   PubMed Web of Science ®Google Scholar
• Wadman M. Public needs to prep for vaccine side effects. Science. 2020;370(6520):1022. doi:10.1126/science.370.6520.1022
   PubMed Web of Science ®Google Scholar
• Maier MA, Jayaraman M, Matsuda S, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Therapy. 2013;21(8):1570–1578.
   PubMed Web of Science ®Google Scholar
• Sabnis S, Kumarasinghe ES, Salerno T, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Therapy. 2018;26(6):1509–1519.
   PubMed Web of Science ®Google Scholar
• Hassett KJ, Benenato KE, Jacquinet E, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Therapy Nucleic Acids. 2019;15:1.
   PubMedGoogle Scholar
• Zhang X, Zhao W, Nguyen GN, et al. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci Adv. 2020;6(34):eabc2315.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li B, Luo X, et al. Biodegradable amino-ester nanomaterials for Cas9 mRNA delivery in vitro and in vivo. ACS Appl Mater Interfaces. 2017;9(30):25481–25487.
   PubMed Web of Science ®Google Scholar
• Jackson NA, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11.
   PubMed Web of Science ®Google Scholar
• Slater RJ. The purification of poly (A)-containing RNA by affinity chromatography. Nucleic Acids. 1984;117–120.
   Google Scholar
• Summer H, Grämer R, Dröge P. Denaturing urea polyacrylamide gel electrophoresis (Urea PAGE). J Visualized Exp. 2009;29(32):e1485.
   Google Scholar
• Aldosari BN, Alfagih IM, Almurshedi AS. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics. 2021;13(2):206.
   PubMed Web of Science ®Google Scholar
• Pascolo S. Vaccination with messenger RNA. DNA Vaccines. 2006;10:23–40.
   Google Scholar
• Weissman D, Pardi N, Muramatsu H, Karikó K. Synthetic messenger RNA and cell metabolism modulation, methods, and protocols. Methods Mol Biol. 2012;969:43–54.
   Google Scholar
• Baiersdörfer M, Boros G, Muramatsu H, et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Therapy Nucleic Acids. 2019;15:26–35.
   PubMedGoogle Scholar
• Weissman D, Pardi N, Muramatsu H, Karikó K. HPLC purification of in vitro transcribed long RNA. Synthetic Messenger RNA Cell Metab Modulation. 2013;43–54.
   Google Scholar
• Zhang RX, Ahmed T, Li LY, Li J, Abbasi AZ, Wu XY. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. Nanoscale. 2017;9(4):1334–1355.
   PubMed Web of Science ®Google Scholar
• Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv. 2014;11(6):885–899.
   PubMed Web of Science ®Google Scholar
• Stump WT, Hall KB. SP6 RNA polymerase efficiently synthesizes RNA from short double-stranded DNA templates. Nucleic Acids Res. 1993;21(23):5480–5484.
   PubMed Web of Science ®Google Scholar
• Edelmann A, Kirchberger J, Naumann M, Kopperschläger G. Generation of catalytically active 6‐phosphofructokinase from Saccharomyces cerevisiae in a cell‐free system. Eur J Biochem. 2000;267(15):4825–4830.
   PubMedGoogle Scholar
• Working PK. Pharmacological-toxicological expert report. CAELYX^. (Stealth^(! R) liposomal doxorubicin HCl). Hum Exp Toxicol. 1996;15:751–785.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12.
   PubMed Web of Science ®Google Scholar
• FDA Approves first-of-its-kind targeted RNA-based therapy to treat a rare disease. FDA. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-targeted-rna-based-therapy-treat-rare-disease. Accessed January 19, 2023.
   Google Scholar
• FDA Approves first COVID-19 vaccine. FDA. Available from:https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine. Accessed January 19, 2023.
   Google Scholar
• Working PK. Pharmacological-toxicological expert report. Hum Exp Toxicol. 1996;15:751–785.
   PubMed Web of Science ®Google Scholar
• Deal CE, Carfi A, Plante OJ. Advancements in mRNA encoded antibodies for passive immunotherapy. Vaccines. 2021;9(2):108.
   Web of Science ®Google Scholar
• Hoerr I, Obst R, Rammensee HG, Jung G. In vivo, the application of RNA leads to the induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30(1):1–7.
   PubMed Web of Science ®Google Scholar
• Hoyer JA, Neundorf I. Peptide vectors for the nonviral delivery of nucleic acids. Acc Chem Res. 2012;45(7):1048–1056.
   PubMed Web of Science ®Google Scholar
• Nakase I, Akita H, Kogure K, et al. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc Chem Res. 2012;45(7):1132–1139.
   PubMed Web of Science ®Google Scholar
• Islam MA, Reesor EK, Xu Y, Zope HR, Zetter BR, Shi J. Biomaterials for mRNA delivery. Biomater sci. 2015;3(12):1519–1533.
   PubMed Web of Science ®Google Scholar
• Li H, Tsui TY, Ma W. Intracellular delivery of molecular cargo using cell-penetrating peptides and the combination strategies. Int J Mol Sci. 2015;16(8):19518–19536.
   PubMed Web of Science ®Google Scholar
• Kallen KJ, Heidenreich R, Schnee M, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines. Hum Vaccin Immunother. 2013;9(10):2263–2276.
   PubMed Web of Science ®Google Scholar
• Scheel B, Teufel R, Probst J, et al. Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA. Eur J Immunol. 2005;35(5):1557–1566.
   PubMed Web of Science ®Google Scholar
• Schnee M, Vogel AB, Voss D, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10(6):e0004746.
   PubMed Web of Science ®Google Scholar
• Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009;32(5):498–507.
   PubMed Web of Science ®Google Scholar
• Stitz L, Vogel A, Schnee M, et al. A thermostable messenger RNA-based vaccine against rabies. PLoS Negl Trop Dis. 2017;11(12):e0006108.
   PubMed Web of Science ®Google Scholar
• Wang Y, Su HH, Yang Y, et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Therapy. 2013;21(2):358–367.
   PubMed Web of Science ®Google Scholar
• Midoux P, Pichon C. Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines. 2015;14(2):221–234.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–1588.
   PubMed Web of Science ®Google Scholar
• Van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9(2):112–124.
   PubMed Web of Science ®Google Scholar
• Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Materials. 2021;6(12):1078–1094.
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy. Nature. 2016;534(7607):396–401.
   PubMed Web of Science ®Google Scholar
• Oberli MA, Reichmuth AM, Dorkin JR, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17(3):1326–1335.
   PubMed Web of Science ®Google Scholar
• Persano S, Guevara ML, Li Z, et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81–89.
   PubMed Web of Science ®Google Scholar
• Miao L, Lin J, Huang Y, et al. Synergistic lipid compositions for albumin receptor-mediated delivery of mRNA to the liver. Nat Commun. 2020;11(1):2424.
   PubMed Web of Science ®Google Scholar
• Patel S, Ashwanikumar N, Robinson E, et al. Naturally occurring cholesterol analogs in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat Commun. 2020;11(1):983.
   PubMed Web of Science ®Google Scholar
• Eygeris Y, Patel S, Jozic A, Sahay G. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 2020;20(6):4543–4549.
   PubMed Web of Science ®Google Scholar
• Guevara ML, Persano F, Persano S. Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front chem. 2020;8:589959.
   PubMed Web of Science ®Google Scholar
• Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proce National Acad Sci. 1987;84(21):7413–7417.
   PubMed Web of Science ®Google Scholar
• Semple SC, Klimuk SK, Harasym TO, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable amino lipids: formation of novel small multilamellar vesicle structures. Biochimica et Biophysica Acta. 2001;1510(1–2):152–166.
   PubMed Web of Science ®Google Scholar
• Semple SC, Klimuk SK, Harasym TO, Hope MJ. Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol. 2000;313:322–341.
   PubMed Web of Science ®Google Scholar
• Kahvejian A, Svitkin YV, Sukarieh R, M’Boutchou MN, Sonenberg N. Mammalian poly (A)-binding protein is a eukaryotic translation initiation factor, which acts via multiple mechanisms. Genes Dev. 2005;19(1):104–113.
   PubMed Web of Science ®Google Scholar
• Tang Z, Zhang X, Shu Y, Guo M, Zhang H, Tao W. Insights from nanotechnology in COVID-19 treatment. Nano Today. 2021;36:101019.
   PubMed Web of Science ®Google Scholar
• Fobian SF, Cheng Z, Ten Hagen TL. Smart lipid-based nanosystems for therapeutic immune induction against cancers: perspectives and outlooks. Pharmaceutics. 2022;14(1):26.
   Web of Science ®Google Scholar
• Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med. 2020;26(3):311–323.
   PubMed Web of Science ®Google Scholar
• Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017;24(3):133–143.
   PubMed Web of Science ®Google Scholar
• Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2021;55(1):2–12.
   PubMed Web of Science ®Google Scholar
• Kauffman KJ, Dorkin JR, Yang JH, et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 2015;15(11):7300–7306.
   PubMed Web of Science ®Google Scholar
• Kuntsche E, Kuntsche S, Knibbe R, et al. Cultural and gender convergence in adolescent drunkenness: evidence from 23 European and North American countries. Arch Pediatr Adolesc Med. 2011;165(2):152–158.
   PubMedGoogle Scholar
• Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking, and endosomal escape. Nat Biotechnol. 2013;31(7):638–646.
   PubMed Web of Science ®Google Scholar
• Li B, Luo X, Deng B, et al. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano Lett. 2015;15(12):8099–8107.
   PubMed Web of Science ®Google Scholar
• Vu MN, Kelly HG, Wheatley AK, et al. Cellular interactions of liposomes and PISA nanoparticles during human blood flow in a microvascular network. Small. 2020;16(33):2002861.
   PubMed Web of Science ®Google Scholar
• Magar KT, Boafo GF, Li X, Chen Z, He W. Liposome-based delivery of biological drugs. Chine Chem Lett. 2022;33(2):587–596.
   Web of Science ®Google Scholar
• Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571.
   PubMed Web of Science ®Google Scholar
• Wanigasekara J, de Carvalho AM, Cullen PJ, Tiwari B, Curtin JF. Converging technologies: targeting the hallmarks of cancer using ultrasound and microbubbles. Trends Cancer. 2021;7(10):886–890.
   PubMed Web of Science ®Google Scholar
• Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles─ from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–17015.
   PubMed Web of Science ®Google Scholar
• Kallen KJ, Theß A. A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines, and drugs. Advances Vaccines. 2014;2(1):10–31.
   PubMedGoogle Scholar
• Read ML, Singh S, Ahmed Z, et al. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. 2005;33(9):e86.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177. doi:10.1016/s0939-6411(00)00087-4
   PubMed Web of Science ®Google Scholar
• Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene-silencing activity in vitro and in vivo. J Controlled Release. 2012;163(3):267–276.
   PubMed Web of Science ®Google Scholar
• Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proce National Acad Sci. 1989;86(16):6077–6081.
   PubMed Web of Science ®Google Scholar
• Dalby B, Cates S, Harris A, et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods. 2004;33(2):95–103.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun C, Wang C, Jankovic KE, Dong Y. Lipids and lipid derivatives for RNA delivery. Chem Rev. 2021;121(20):12181–12277.
   PubMed Web of Science ®Google Scholar
• Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J Controlled Release. 2006;116(2):255–264.
   PubMed Web of Science ®Google Scholar
• Hirsch-Lerner D, Zhang M, Eliyahu H, Ferrari ME, Wheeler CJ, Barenholz Y. Effect of “helper lipid” on lipoplex electrostatics. Biochimica et Biophysica Acta. 2005;1714(2):71–84.
   PubMed Web of Science ®Google Scholar
• Wasungu L, Stuart MC, Scarzello M, Engberts JB, Hoekstra D. Lipoplexes formed from sugar-based gemini surfactants undergo a lamellar-to-micellar phase transition at acidic pH. Evidence for a non-inverted membrane-destabilizing hexagonal phase of lipoplexes. Biochimica et Biophysica Acta. 2006;1758(10):1677–1684.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Satapathy SR, Dutta T. Delivery strategies for mRNA vaccines. Pharmaceut Med. 2022;36(1):11–20.
   PubMed Web of Science ®Google Scholar
• de Ilarduya CT, Arangoa MA, Düzgüneş N. Transferrin-lipoplexes with protamine-condensed DNA for serum-resistant gene delivery. Methods Enzymol. 2003;373:342–356.
   PubMed Web of Science ®Google Scholar
• Hoekstra D, Scherphof G. Effect of fetal calf serum and serum protein fractions on the uptake of liposomal phosphatidylcholine by rat hepatocytes in primary monolayer culture. Biochimica et Biophysica Acta. 1979;551(1):109–121.
   PubMedGoogle Scholar
• Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem. 1992;267(26):18759–18765.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–138.
   PubMed Web of Science ®Google Scholar
• Bailey AL, Cullis PR. Modulation of membrane fusion by asymmetric trans bilayer distributions of amino lipids. Biochemistry. 1994;33(42):12573–12580.
   PubMed Web of Science ®Google Scholar
• Żak MM, Zangi L. Lipid nanoparticles for organ-specific mRNA therapeutic delivery. Pharmaceutics. 2021;13(10):1675.
   PubMed Web of Science ®Google Scholar
• Thevenot J, Troutier AL, David L, Delair T, Ladavière C. Steric stabilization of lipid/polymer particle assemblies by poly (ethylene glycol)-lipids. Biomacromolecules. 2007;8(11):3651–3660.
   PubMed Web of Science ®Google Scholar
• Li M, Wang Z, Xie C, Xia X. Advances in mRNA vaccines. Int Rev Cell Mol Biol. 2022:65.
   PubMedGoogle Scholar
• Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14–20.
   PubMed Web of Science ®Google Scholar
• Leung AK, Hafez IM, Baoukina S, et al. Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces. 2012;116(34):18440–18450. doi:10.1021/jp303267y
   PubMed Web of Science ®Google Scholar
• Ross J. mRNA stability in mammalian cells. Microbiol Rev. 1995;59(3):423–450.
   PubMedGoogle Scholar
• Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012;109(36):14604–14609. doi:10.1073/pnas.1209367109
   PubMed Web of Science ®Google Scholar
• Tam YY, Chen S, Cullis PR. Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics. 2013;5(3):498–507.
   PubMedGoogle Scholar
• Brito LA, Chan M, Shaw CA, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Therapy. 2014;22(12):2118–2129.
   PubMed Web of Science ®Google Scholar
• Jeeva S, Kim KH, Shin CH, Wang BZ, Kang SM. An update on mRNA-based viral vaccines. Vaccines. 2021;9(9):965.
   Web of Science ®Google Scholar
• Gordon S, Plüddemann A, Mukhopadhyay S. Sinusoidal immunity: macrophages at the lymphohematopoietic interface. Cold Spring Harb Perspect Biol. 2015;7(4):a016378.
   Web of Science ®Google Scholar
• Heesters BA, van der Poel CE, Das A, Carroll MC. Antigen presentation to B cells. Trends Immunol. 2016;37(12):844–854.
   PubMed Web of Science ®Google Scholar
• Ionescu L, Urschel S. Memory B cells and long-lived plasma cells. Transplantation. 2019;103(5):890–898.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Sakurai Y, Anindita J, Akita H. Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapse. Adv Drug Deliv Rev. 2020;154:210–226.
   PubMed Web of Science ®Google Scholar
• Fenton OS, Kauffman KJ, Kaczmarek JC, et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv Mater. 2017;29(33):1606944.
   Web of Science ®Google Scholar
• Rodrigueza WV, Wheeler JJ, Klimuk SK, Kitson CN, Hope MJ. Transbilayer movement and net flux of cholesterol and cholesterol sulfate between liposomal membranes. Biochemistry. 1995;34(18):6208–6217.
   PubMed Web of Science ®Google Scholar
• Herrera M, Kim J, Eygeris Y, Jozic A, Sahay G. Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery. Biomater Sci. 2021;9(12):4289–4300.
   PubMed Web of Science ®Google Scholar
• Zadory M, Lopez E, Babity S, Gravel SP, Brambilla D. Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression. Biomater Sci. 2022.
   PubMed Web of Science ®Google Scholar
• Zuhorn IS, Bakowsky U, Polushkin E, et al. Nonbilayer phase of lipoplex–membrane mixture determines endosomal escape of genetic cargo and transfection efficiency. Mol Therapy. 2005;11(5):801–810.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
   PubMed Web of Science ®Google Scholar
• Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D. Nanomaterial delivery systems for mRNA vaccines. Vaccines. 2021;9(1):65.
   PubMed Web of Science ®Google Scholar
• Heyes J, Hall K, Tailor V, Lenz R, MacLachlan I. Synthesis and characterization of novel poly (ethylene glycol)-lipid conjugates suitable for use in drug delivery. J Controlled Release. 2006;112(2):280–290.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160.
   PubMed Web of Science ®Google Scholar
• Woodle MC. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev. 1998;32(1–2):139–152.
   PubMed Web of Science ®Google Scholar
• Leung AK, Tam YY, Cullis PR. Lipid nanoparticles for short interfering RNA delivery. Adv Genet. 2014;88:71–110.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochimica et Biophysica Acta. 2009;1788(10):2259–2266.
   PubMed Web of Science ®Google Scholar
• Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32(1):32–45.
   PubMed Web of Science ®Google Scholar
• Kumar V, Qin J, Jiang Y, et al. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. Mol Therapy Nucleic Acids. 2014;3:e210.
   PubMedGoogle Scholar
• Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv Drug Deliv Rev. 2020;154:37–63.
   PubMed Web of Science ®Google Scholar
• Tabrez S, Jabir NR, Adhami VM, et al. Nanoencapsulated dietary polyphenols for cancer prevention and treatment: successes and challenges. Nanomedicine. 2020;15(11):1147–1162.
   PubMed Web of Science ®Google Scholar
• Zhu X, Tao W, Liu D, et al. Surface De-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo. Theranostics. 2017;7(7):1990.
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172–176.
   PubMed Web of Science ®Google Scholar
• Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proce National Acad Sci. 2010;107(5):1864–1869.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Sahay G, Li GZ, et al. Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery. Mol Therapy. 2011;19(9):1688–1694.
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 2013;36(6):892–899.
   PubMed Web of Science ®Google Scholar
• Fang Y, Xue J, Gao S, et al. Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” inefficient drug delivery. Drug Deliv. 2017;24(2):22–32.
   PubMed Web of Science ®Google Scholar
• Harvie P, Wong FM, Bally MB. Use of poly (ethylene glycol)–lipid conjugates to regulate the surface attributes and transfection activity of lipid–DNA particles. J Pharm Sci. 2000;89(5):652–663.
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Kogure K, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 2007;14(1):68–77.
   PubMed Web of Science ®Google Scholar
• Song LY, Ahkong QF, Rong Q, et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochimica et Biophysica Acta. 2002;1558(1):1–3.
   PubMed Web of Science ®Google Scholar
• Judge A, McClintock K, Phelps JR, MacLachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Therapy. 2006;13(2):328–337.
   PubMed Web of Science ®Google Scholar
• Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016;99:129–137.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Wei T, Jia Y, et al. Dendrimer‐based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Adv Mater. 2018;30(52):1805308.
   Web of Science ®Google Scholar
• Koltover I, Salditt T, Rädler JO, Safinya CR. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science. 1998;281(5373):78–81.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Eng J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Xiao Y, Tang Z, Huang X, et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem Soc Rev. 2022.
   Web of Science ®Google Scholar
• Zeng C, Zhang C, Walker PG, Dong Y. Formulation and delivery technologies for mRNA vaccines. Cham: Springer International Publishing; 2020.
   Google Scholar
• Li M, Li Y, Peng K, et al. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. Acta biomaterials. 2017;64:237–248.
   PubMed Web of Science ®Google Scholar
• Wu GY, Wu CH. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem. 1987;262(10):4429–4432.
   PubMed Web of Science ®Google Scholar
• Démoulins T, Milona P, Englezou PC, et al. Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine. 2016;12(3):711–722.
   PubMed Web of Science ®Google Scholar
• Ghosh B, Biswas S. Polymeric micelles in cancer therapy: state of the art. J Controlled Release. 2021;332:127–147.
   PubMed Web of Science ®Google Scholar
• Ghezzi M, Pescina S, Padula C, et al. Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. J Controlled Release. 2021;332:312–336.
   PubMed Web of Science ®Google Scholar
• McKinlay CJ, Vargas JR, Blake TR, et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proce National Acad Sci. 2017;114(4):E448–56.
   PubMed Web of Science ®Google Scholar
• Jere D, Jiang HL, Arote R, et al. Degradable polyethyleneimine as DNA and small interfering RNA carriers. Expert Opin Drug Deliv. 2009;6(8):827–834.
   PubMed Web of Science ®Google Scholar
• Blakney AK, Zhu Y, McKay PF, et al. Big is beautiful: enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer. ACS Nano. 2020;14(5):5711–5727.
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine. 2009;27(25–26):3345–3348.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12(1):13–30.
   PubMed Web of Science ®Google Scholar
• Teixeira H, Dubernet C, Puisieux F, Benita S, Couvreur P. Submicron cationic emulsions as a new delivery system for oligonucleotides. Pharm Res. 1999;16:30–36.
   PubMed Web of Science ®Google Scholar
• Teixeira HF, Bruxel F, Fraga M, et al. Cationic nanoemulsions as nucleic acids delivery systems. Int J Pharm. 2017;534(1–2):356–367.
   PubMed Web of Science ®Google Scholar
• Anderluzzi G, Lou G, Gallorini S, et al. Investigating the impact of delivery system design on the efficacy of self-amplifying RNA vaccines. Vaccines. 2020;8(2):212.
   Web of Science ®Google Scholar
• Erasmus JH, Khandhar AP, O’Connor MA, et al. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med. 2020;12(555):eabc9396.
   PubMed Web of Science ®Google Scholar
• Erasmus JH, Khandhar AP, Walls AC, et al. Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates. bioRxiv. 2020;2020–2025.
   Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184(2):465–472.
   PubMed Web of Science ®Google Scholar
• Tateshita N, Miura N, Tanaka H, et al. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine. J Controlled Release. 2019;310:36–46.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood J Am Soc Hematol. 2001;98(1):49–56.
   Google Scholar
• McNamara MA, Nair SK, Holl EK. RNA-Based Vaccines in Cancer Immunotherapy. J Immunol Res. 2015;2015:9.
   Web of Science ®Google Scholar
• Benteyn D, Heirman C, Bonehill A, Thielemans K. mRNA-based dendritic cell vaccines. Expert Rev Vaccines. 2015;14(2):161–176.
   PubMed Web of Science ®Google Scholar
• Perche F, Benvegnu T, Berchel M, et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipo polyplexes loaded with tumor antigen messenger RNA. Nanomedicine. 2011;7(4):445–453.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grünebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol. 2008;65(3):191–199.
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009;66:2873–2896.
   PubMed Web of Science ®Google Scholar
• Doherty GJ, McMahon HT. Mechanisms of Endocytosis. Annu Rev Biochem. 2009;78:857–902.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang L. A window onto siRNA delivery. Nat Biotechnol. 2013;31(7):611–612.
   PubMed Web of Science ®Google Scholar
• Rzigalinski BA, Carfagna CS, Ehrich M. Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(4):e1444.
   Web of Science ®Google Scholar
• Kim J, Narayana A, Patel S, Sahay G. Advances in intracellular delivery through supramolecular self-assembly of oligonucleotides and peptides. Theranostics. 2019;9(11):3191.
   PubMed Web of Science ®Google Scholar
• Rejman J, Bragonzi A, Conese M. Role of clathrin-and caveolae-mediated endocytosis in gene transfer mediated by lipo-and polyplexes. Mol therapy. 2005;12(3):468–474.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Kogo H, Nomura R, Une T. Isoforms of caveolin-1 and caveolar structure. J Cell Sci. 2000;113(19):3509–3517.
   PubMed Web of Science ®Google Scholar
• Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol. 2010;11(1):50–61.
   PubMed Web of Science ®Google Scholar
• Maugeri M, Nawaz M, Papadimitriou A, et al. Linkage between the endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat Commun. 2019;10(1):4333.
   PubMed Web of Science ®Google Scholar
• Uchida S, Perche F, Pichon C, Cabral H. Nanomedicine-based approaches for mRNA delivery. Mol Pharm. 2020;17(10):3654–3684.
   PubMed Web of Science ®Google Scholar
• Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J Controlled Release. 2011;151(3):220–228.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Lu Q, Wang Y, et al. Quantitating endosomal escape of a library of polymers for mRNA delivery. Nano Lett. 2020;20(2):1117–1123.
   PubMed Web of Science ®Google Scholar
• Wu Z, Li T. Nanoparticle-mediated cytoplasmic delivery of messenger RNA vaccines: challenges and future perspectives. Pharm Res. 2021;38:473–478.
   PubMed Web of Science ®Google Scholar
• Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83–112.
   PubMed Web of Science ®Google Scholar
• Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumor-targeted drug delivery: a review. Biomaterials. 2016;85:152–167.
   PubMed Web of Science ®Google Scholar
• Li B, Zhang X, Dong Y. Nanoscale platforms for messenger RNA delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(2):e1530.
   PubMed Web of Science ®Google Scholar
• Midoux P, Roche AC, Monsigny M. Quantitation of the binding, uptake, and degradation of fluoresceinylated neoglycoproteins by flow cytometry. Cytometry. 1987;8(3):327–334.
   PubMedGoogle Scholar
• Murphy RF, Powers S, Cantor CR. Endosome pH measured in single cells by dual fluorescence flow cytometry: rapid acidification of insulin to pH 6. J Cell Biol. 1984;98(5):1757–1762.
   PubMed Web of Science ®Google Scholar
• Sago CD, Lokugamage MP, Lando GN, et al. Modifying a commonly expressed endocytic receptor retargets nanoparticles in vivo. Nano Lett. 2018;18(12):7590–7600.
   PubMed Web of Science ®Google Scholar
• Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Controlled Release. 2015;217:345–351.
   PubMed Web of Science ®Google Scholar
• Melo M, Porter E, Zhang Y, et al. Immunogenicity of RNA replicons encoding HIV Env immunogens designed for self-assembly into nanoparticles. Mol Therapy. 2019;27(12):2080–2090.
   PubMed Web of Science ®Google Scholar
• Karer M, Stiasny K, Zeitlinger M, Jilma B. Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?. Blood Coagulation Fibrinolysis. 2021;32(6):423.
   PubMed Web of Science ®Google Scholar
• Chen Q, Qi R, Chen X, et al. A targeted and stable polymeric nanoformulation enhances systemic delivery of mRNA to tumors. Mol Therapy. 2017;25(1):92–101.
   PubMed Web of Science ®Google Scholar
• Lindgren G, Ols S, Liang F, et al. Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol. 2017;8:1539.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang W, Wang S. Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines. 2015;14(11):1509–1523.
   PubMed Web of Science ®Google Scholar
• Lindsay KE, Bhosle SM, Zurla C, et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging. Nature Biomed Eng. 2019;3(5):371–380.
   PubMed Web of Science ®Google Scholar
• Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319–1330.
   PubMed Web of Science ®Google Scholar
• Mockey M, Bourseau E, Chandrashekhar V, et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipo polyplexes. Cancer Gene Ther. 2007;14(9):802–814.
   PubMed Web of Science ®Google Scholar
• Homayun B, Lin X, Choi HJ. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics. 2019;11(3):129.
   PubMed Web of Science ®Google Scholar
• Mauro VP, Chappell SA. A critical analysis of codon optimization in human therapeutics. Trends Mol Med. 2014;20(11):604–613.
   PubMed Web of Science ®Google Scholar
• Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles. J Controlled Release. 2006;112(1):26–34.
   PubMed Web of Science ®Google Scholar
• Nicholson LB. The immune system. Essays Biochem. 2016;60:275–301.
   PubMed Web of Science ®Google Scholar
• Wang F, Kream RM, Stefano GB. An evidence-based perspective on mRNA-SARS-CoV-2 vaccine development. Med sci monitor. 2020;26:e924700–1.
   PubMed Web of Science ®Google Scholar
• Turner MR, Balu-Iyer SV. Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. J Pharm Sci. 2018;107(5):1247–1260.
   PubMed Web of Science ®Google Scholar
• Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: a literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36:2986–2996.
   PubMed Web of Science ®Google Scholar
• Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self-antigen. Cancer Immunol Immunother. 2006;55(6):672–683.
   PubMed Web of Science ®Google Scholar
• Tan L, Zheng T, Li M, et al. Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates. Drug Deliv Transl Res. 2020;10:678–689.
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Therapy. 2017;25(6):1316–1327.
   PubMed Web of Science ®Google Scholar
• Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326–3334.
   PubMed Web of Science ®Google Scholar
• Zangi L, Lui KO, Von Gise A, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013;31(10):898–907.
   PubMed Web of Science ®Google Scholar
• Turnbull IC, Eltoukhy AA, Fish KM, et al. Myocardial delivery of lipidoid nanoparticle-carrying modRNA induces rapid and transient expression. Mol Therapy. 2016;24(1):66–75.
   PubMed Web of Science ®Google Scholar
• Patel S, Ryals RC, Weller KK, Pennesi ME, Sahay G. Lipid nanoparticles for delivery of messenger RNA to the back of the eye. J Controlled Release. 2019;303:91–100.
   PubMed Web of Science ®Google Scholar
• Ryals RC, Patel S, Acosta C, McKinney M, Pennesi ME, Sahay G. The effects of PEGylation on LNP-based mRNA delivery to the eye. PLoS One. 2020;15(10):e0241006.
   PubMed Web of Science ®Google Scholar
• Devoldere J, Peynshaert K, Dewitte H, et al. Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration. J Controlled Release. 2019;307:315–330.
   PubMed Web of Science ®Google Scholar
• Nabhan JF, Wood KM, Rao VP, et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia. Sci Rep. 2016;6(1):20019.
   PubMedGoogle Scholar
• Anderson DM, Hall LL, Ayyalapu AR, Irion VR, Nantz MH, Hecker JG. Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system. Hum Gene Ther. 2003;14(3):191–202.
   PubMed Web of Science ®Google Scholar
• Li Y, Su Z, Zhao W, et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nature Cancer. 2020;1(9):882–893.
   PubMedGoogle Scholar
• Li Y, Teague B, Zhang Y, et al. In vitro evolution of enhanced RNA replicons for immunotherapy. Sci Rep. 2019;9(1):1.
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Blake TR, McKinlay CJ, et al. Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res. 2019;79(7):1624–1634.
   PubMed Web of Science ®Google Scholar
• Hewitt SL, Bai A, Bailey D, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci Transl Med. 2019;11(477):eaat9143.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, et al. Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral ImmunityAntitumoral Immunity by Intranodal Vaccination with RNA. Cancer Res. 2010;70(22):9031–9040.
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Eng J Med. 2004;350(9):896–903.
   PubMed Web of Science ®Google Scholar
• Mai Y, Guo J, Zhao Y, Ma S, Hou Y, Yang J. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell Immunol. 2020;354:104143.
   PubMed Web of Science ®Google Scholar
• Shakya AK, Chowdhury MY, Tao W, Gill HS. Mucosal vaccine delivery: Current state and a pediatric perspective. J Controlled Release. 2016;240:394–413.
   PubMed Web of Science ®Google Scholar
• Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2006;208(2):270–282.
   PubMed Web of Science ®Google Scholar
• Baba M, Itaka K, Kondo K, Yamasoba T, Kataoka K. Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles. J Controlled Release. 2015;201:41–48.
   PubMed Web of Science ®Google Scholar
• Kulkarni JA, Darjuan MM, Mercer JE, et al. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano. 2018;12(5):4787–4795.
   PubMed Web of Science ®Google Scholar
• Crommelin DJ, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110(3):997–1001.
   PubMed Web of Science ®Google Scholar
• Pogocki D, Schöneich C. Chemical stability of nucleic acid–derived drugs. J Pharm Sci. 2000;89(4):443–456.
   PubMed Web of Science ®Google Scholar
• Holm MR, Poland GA. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy. Vaccine. 2021;39(3):457.
   PubMed Web of Science ®Google Scholar
• Chen S, Ren J, Chen R. Cryopreservation and desiccation preservation of cells. Compreh Biotechnol. 2019;5:157–166.
   Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of an mRNA rabies vaccine in healthy adults: an open-label, non-randomized, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511–1520.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688–1713.
   PubMed Web of Science ®Google Scholar
• Dolgin E. How COVID unlocked the power of RNA vaccines. Nature. 2021;589(7841):189–192.
   PubMed Web of Science ®Google Scholar
• Muramatsu H, Lam K, Bajusz C, et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Therapy. 2022;30(5):1941–1951.
   PubMed Web of Science ®Google Scholar
• Zhao P, Hou X, Yan J, et al. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioactive Materials. 2020;5(2):358–363.
   PubMed Web of Science ®Google Scholar
• Qin S, Tang X, Chen Y, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction Targeted Therapy. 2022;7(1):166.
   PubMed Web of Science ®Google Scholar
• Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA cancer vaccines. Curr Strategies Cancer Gene Therapy. 2016;2:61–85.
   Google Scholar
• Coulie PG, Van den Eynde BJ, van der Bruggen P, et al. TumourantigensrecognizedbyTlymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer. 2014;14:135–146.
   PubMed Web of Science ®Google Scholar
• Laureano RS, Sprooten J, Vanmeerbeerk I, et al. Trial watch Dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology. 2022;11(1):2096363.
   PubMed Web of Science ®Google Scholar
• Poorebrahim M, Abazari MF, Sadeghi S, et al. Genetically modified immune cells targeting tumor antigens. Pharmacol Ther. 2020;214:107603.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Ying H, Hwang L, Leitner WW. The promise of nucleic acid vaccines. Gene Ther. 2000;7(2):89–92.
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature. 2001;413(6857):732–738.
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(7089):101–105.
   PubMed Web of Science ®Google Scholar
• Nallagatla SR, Hwang J, Toroney R, Zheng X, Cameron CE, Bevilacqua PC. 5’-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science. 2007;318(5855):1455–1458.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Eng J Med. 2020;383(20):1920–1931.
   PubMed Web of Science ®Google Scholar
• Trepotec Z, Lichtenegger E, Plank C, Aneja MK, Rudolph C. Delivery of mRNA therapeutics for the treatment of hepatic diseases. Mol Therapy. 2019;27(4):794–802.
   PubMed Web of Science ®Google Scholar
• Magadum A, Kaur K, Zangi L. mRNA-based protein replacement therapy for the heart. Mol Therapy. 2019;27(4):785–793.
   PubMed Web of Science ®Google Scholar
• Warren L, Lin C. mRNA-based genetic reprogramming. Mol Therapy. 2019;27(4):729–734.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine. Clinical trials.gov. Available from: https://clinicaltrials.gov/. Accessed July 14, 2023.
   Google Scholar
• Yihunie W, Kebede B, Tegegne BA, et al. Systematic Review of Safety of RTS, S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults. Clin Pharmacol. 2023;15:21–32.
   PubMedGoogle Scholar